Gelesis Holdings, Inc. operates as a biotechnology company. The company is headquartered in Boston, Massachusetts and currently employs 93 full-time employees. The company went IPO on 2020-07-07. The firm focuses on advancing superabsorbent hydrogel therapeutics for chronic gastrointestinal (GI) diseases including excess weight, type two diabetes, Nonalcoholic Fatty Liver Disease (NAFLD)/ Nonalcoholic Steatohepatitis (NASH), functional constipation (FC), and inflammatory bowel disease. Its product, Plenity, is an orally administered capsule. Plenity is available by prescription via a telehealth consultation with a physician trained in weight management support, with free, unlimited follow-up visits as needed. Consumers can visit myplenity.com for online consultations. Its other pipeline candidate includes GS200 for weight loss in prediabetes and type two diabetes. The company is also developing GS300 for the treatment of NAFLD and NASH, and GS500 for the treatment of Functional Constipation (FC).

Industry: Pharmaceutical Preparations Peers: Assembly Biosciences Inc aTyr Pharma Inc Axcella Health Inc. Surrozen Inc Fortress Biotech Inc Cue Biopharma Inc PDS Biotechnology Corp /entities/fnchq Palvella Therapeutics Inc